Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study
Authors:
- for the CanIMPACT TeamFTfor the CanIMPACT Team
- Mary L. McBrideMMMary L. McBride
Open Access
- 4 July 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-11
Abstract
In order to maximize later health, there are established components and guidelines for quality follow-up care of breast cancer survivors. However, adherence to quality follow-up in Canada may not be optimal, and may vary by province. We determined and compared the proportion of patients in each province who received adherent and non-adherent surveillance for recurrence, new cancers and late effects, recommended preventive care, and recommended physician visits for comorbidities. Cohorts consisted of all adult women diagnosed with incident invasive breast cancer between 2007 and 2010/2012 in four Canadian provinces (British Columbia (BC) N = 9338; Manitoba N = 2688; Ontario N = 23,700; Nova Scotia (NS) N = 2735), identified from provincial cancer registries, alive and cancer-free at 30 months post-diagnosis. Their healthcare utilization was determined from one to 5 years post-treatment, using linked administrative databases. Adherence, underuse, and overuse of recommended services were evaluated yearly and compared using descriptive statistics. In all provinces and follow-up years, the majority of survivors had more than the recommended number of visits to either an oncologist or primary care physician (range 53.8% NS Year 3; 85.8% Ontario Year 4). The proportion of patients with the guideline-recommended number of oncologist visits varied by province (range 29.8% BC Year 5; 74.8% Ontario Year 5), and the proportion of patients with less than the recommended number of specified breast cancer-related visits with either an oncologist or primary care physician ranged from 32.6% (Ontario Year 2) to 84.4% (NS Year 3). Underuse of surveillance breast imaging was identified in NS and BC. The proportion of patients receiving imaging for metastatic disease (not recommended in the guidelines) in BC, Manitoba, and Ontario (not reported in NS) ranged from 20.3% (BC Year 5) to 53.3% (Ontario Year 2). Compliance with recommended physician visits for patients with several chronic conditions was high in Ontario and NS. Preventive care was less than optimal in all provinces with available data. Quality of breast cancer survivor follow-up care varies among provinces. Results point to exploration of factors affecting differences, province-specific opportunities for care improvement, and the value of administrative datasets for health system assessment.Keywords
Funding Information
- Canadian Institutes of Health Research (128272)
This publication has 51 references indexed in Scilit:
- Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancerBreast Cancer Research and Treatment, 2011
- Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort studyBreast Cancer Research, 2011
- Late effects of breast cancer treatment and potentials for rehabilitationActa Oncologica, 2011
- Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9BMC Cancer, 2011
- Population-Based Longitudinal Study of Follow-Up Care for Breast Cancer SurvivorsJournal of Oncology Practice, 2010
- Second Primary Breast Cancer Occurrence According to Hormone Receptor StatusJNCI: Journal of the National Cancer Institute, 2009
- Impact of Acquired Comorbidities on All-Cause Mortality Rates Among Older Breast Cancer SurvivorsMedical Care, 2009
- The Utility of Administrative Data for Measuring Adherence to Cancer Surveillance Care GuidelinesMedical Care, 2007
- Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast CancerNew England Journal of Medicine, 1992